During optimization,robust cell-based activity was achieved, creating a near-completereduction (>80%) in symmetric dimethyl arginine (SDMA) leadingtodecreased cell viability of MTAP-del HCT116 cancer cells. This evidence concerns the gene MTAP and cancer.